Keymed Biosciences Inc. (HKG:2162)

Keymed Biosciences Ratios and Metrics

Market cap in millions HKD. Fiscal year is January - December.

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	May 27, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Market Capitalization	17,529	15,746	8,516	13,586	14,174	9,651
Market Cap Growth	36.78%	84.90%	-37.32%	-4.15%	46.87%	-
Enterprise Value	16,266	13,639	6,526	10,725	10,331	15,170
Last Close Price	59.50	53.45	30.90	49.10	51.00	34.50
PS Ratio	21.99	19.75	18.69	34.83	125.30	71.30
PB Ratio	5.68	5.10	3.23	4.13	3.76	2.16
P/TBV Ratio	5.69	5.12	3.25	4.13	3.76	2.15
EV/Sales Ratio	20.41	17.11	14.32	27.49	91.33	112.08
Debt / Equity Ratio	0.28	0.28	0.30	0.14	0.04	0.01
Net Debt / Equity Ratio	-0.41	-0.41	-0.57	-0.77	-0.91	-0.96
Net Debt / EBITDA Ratio	2.07	2.07	2.55	5.67	5.85	10.02
Net Debt / FCF Ratio	1.09	1.09	1.41	3.37	4.49	9.02
Asset Turnover	0.18	0.18	0.11	0.09	0.03	0.05
Inventory Turnover	0.53	0.53	0.13	0.66	0.07	1.02
Quick Ratio	2.49	2.49	3.04	8.80	8.45	31.55
Current Ratio	2.90	2.90	3.30	9.36	8.72	31.96
Return on Equity (ROE)	-19.91%	-19.91%	-18.85%	-11.31%	-8.69%	-305.24%
Return on Assets (ROA)	-9.88%	-9.88%	-10.23%	-7.32%	-8.65%	-10.09%
Return on Capital Employed (ROCE)	-18.70%	-18.70%	-20.70%	-12.80%	-15.30%	-9.40%
Earnings Yield	-3.32%	-3.69%	-6.44%	-2.91%	-2.46%	-49.44%
FCF Yield	-6.64%	-7.40%	-12.46%	-5.53%	-5.43%	-4.92%
Buyback Yield / Dilution	-4.59%	-4.59%	-0.22%	-0.09%	-62.34%	-139.72%

Source: S&P Global Market Intelligence. Standard template. Financial Sources.